KTOV ($16 M) (Cash $17 M) US-NDA Submission this Quarter Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : KTOV ($16 M) (Cash $17 M) US-NDA Submission this Quarter

KTOV 4.610

-0.9%

Jan 22 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	10/6/2017 10:16:51 AM
	of 5

Dirt cheap low float stock with HUGE upside potential Kitov Announces FDA Acceptance of NDA for KIT-302 baystreet.ca KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain. KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market. Expected Upcoming Milestones ¦Q4 2017 – Top-line results from Phase III kidney function trial. ¦Q2 2018 – Expected FDA approval decision for KIT-302.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next